Migd-061 Jun 2026

| Model | Dosing Regimen | Endpoints & Results | |-------|----------------|---------------------| | | 30 mg/kg PO QD, 21 days | Tumor growth inhibition (TGI) = 62 % vs. vehicle; enhanced CD8⁺ T‑cell infiltration (↑ 2.3‑fold). | | Humanized NSG mouse xenograft (A549) + anti‑PD‑1 | MIGD‑061 15 mg/kg PO QD + pembrolizumab 10 mg/kg IP Q3D | Combination TGI = 84 % (vs. 48 % for pembrolizumab alone). | | SOD1‑G93A ALS mouse model | 10 mg/kg PO BID, started at P60 | Delayed onset of motor decline by 12 days; ↑ survival median + 8 days (p = 0.03). | | Dengue virus (DENV‑2) in AG129 mice | 25 mg/kg PO BID, 5 days post‑infection | Viral load in serum ↓ 1.7 log₁₀; survival 70 % vs. 30 % in control. |

If you provide those details, I can write a clear, structured feature like: migd-061

To help you write a about it, could you clarify: | Model | Dosing Regimen | Endpoints &